Develops psychedelic therapeutics for the treatment of mental health disorders.
Cybin Inc., headquartered in Toronto, Canada, is a biopharmaceutical company specializing in the development of psychedelic-based therapeutics. The company is committed to advancing treatments that harness the potential of psychedelic compounds to address a range of mental health disorders.
At the forefront of Cybin's development pipeline is CYB003, a deuterated psilocybin analog aimed at treating major depressive disorder and alcohol use disorders. Additionally, CYB004, a deuterated dimethyltryptamine, is being developed for the treatment of anxiety disorders, while CYB005 focuses on a phenethylamine derivative targeting neuroinflammation. These innovative therapies represent Cybin's dedication to expanding treatment options for patients struggling with various psychiatric conditions.
Cybin has also pioneered EMBARK, a psychedelic-assisted psychotherapy approach designed to enhance therapeutic outcomes through the careful integration of psychedelic compounds with psychotherapeutic practices. With a robust research and development strategy, Cybin Inc. is poised to lead advancements in psychedelic medicine, striving to improve mental health outcomes globally.